Search Results 691-700 of 18070 for Alopecia

1. A Study to Test Adding Pembrolizumab to Olaparib Alone as Therapy for Patients with Pancreatic Cancer That Has Spread with Inherited BRCA Mutations - Mayo Clinic

   ... alopecia. Zubrod performance status of 0-1. Patients must have a complete medical history and physical exam within 28 days prior to registration: Absolute ...

2. TheraSphere With and Without Durvalumab and Tremelimumab for HCC - Mayo Clinic

   Patients with vitiligo or alopecia 2. Patients with hypothyroidism (e.g. following Hashimoto's syndrome) stable on hormone replacement therapy 3. Any ...

3. Meet The Faculty - Dermatopathology Fellowship (Minnesota) - Mayo Clinic College of Medicine & Science

   Her clinical and academic interests include autoimmune blistering disease, alopecia, and digital pathology. Outside of work, you might find her training for ...

4. A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Impaired Renal Function - Mayo Clinic

   Any unresolved toxicity ≥ Grade 2 from previous treatment except for alopecia, or peripheral neuropathy up to Grade 2. Plasmapheresis within 7 days prior ...

5. Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study - Mayo Clinic

   ... alopecia or vitiligo). PRE-REGISTRATION: Hemoglobin >= 9.0 g/dL (obtained =< 28 days prior to pre-registration) (Must be >= 7 days after most recent ...

6. Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer - Mayo Clinic

   ... alopecia, oxaliplatin-related neuropathy, asymptomatic electrolyte abnormalities, and other non-clinically significant adverse events. - Any of the ...

7. A Study to Evaluate HKI-272 and Capecitabine for HER2-Positive Breast Cancer and Brain Metastases - Mayo Clinic

   ... alopecia). Washout from trastuzumab or hormonal therapy is not required. Participants who are currently receiving any other investigational agents. History ...

8. Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer - Mayo Clinic

   Note: Subjects with ≤ Grade 2 neuropathy or any grade of alopecia are an exception to this criterion and will qualify for the study. Note: If subjects ...

9. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Resolution of prior therapy-related AEs (including immune-related AEs but excluding alopecia) to ≤ Grade 1 (except for Grade 2 peripheral neuropathy) per CTCAE ...

10. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer - Mayo Clinic

    ... alopecia and oxaliplatin induced neurotoxicity ≤ grade 2; Albumin levels > 2.5; Any of the following: Pregnant women; Nursing women; Men or women of ...